HIGHLIGHTS
SUMMARY
There are limited data on the efficacy of taxane-based chemotherapy for AR-V7-positive CRPC. This prospective, real-world study aims to investigate if CBZ is equally effective in AR-V7-positive and ARV7-negative CRPC, and if AR-V7-positive patients retain CBZ sensitivity. There was no significant difference in PSA best change rate between the CTC-negative/AR-V7-positive, CTC-positive/AR-V7-negative, and CTC-positive/AR-V7-positive groups. PSA-RR (≥ 50%) was observed in 43% (6/14) of the patients in the CTC-negative/AR-V7-negative . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.